Genetic screening for haematological cancers

Screening for haematological cancers is costly and time-consuming. The standard screening procedure, which looks for mutations in four specific genes, costs about $300 and can take seven to 10 days to return complete results. To allay the costs involved, many hospitals wait for a batch of samples from multiple patients before running the test. Precipio, based in New Haven, has now advanced the state of care with the commercial launch of HemeScreen, a novel proprietary test for mutations in haematological cancers.

Importantly, the HemeScreen assay can deliver results in four to six hours rather than days, enabling a same-day turnaround time. Equally important, the HemeScreen assay also costs a fraction of the current technologies to run. At $100, this is about one-third of the cost of the traditional method, making the potential savings substantial.

 

Other news

Upcoming Events

Managing Cultural Differences in the Workplace

The Holiday Inn - Kensington Forum, 97 Cromwell Road, London SW7 4DN
21 January 2019

British Society for Haematology Paediatric Symposium

Royal College of Paediatrics and Child Health, 5-11 Theobalds Road, London WC1X 8SH
14 February 2019

Challenges in the clinical biochemistry laboratory and beyond

The Royal College of Pathologists
28 February 2019

British Society for Haematology 59th Annual Scientific Meeting

SEC Glasgow
1-3 April 2019

Focus 2019

SEC Glasgow
1-3 May 2019

Latest Issue

Pathology In Practice

Pathology In Practice

Dec 2018

Molecular diagnostics and LAMP technology

Register now to apply for regular copies of Pathology In Practice and free access to premium content, as well as our regular newsletters.